Acino Holding AG : Acino: Publicity duties

NEWS RELEASE - PRESSEMITTEILUNG

Acino: Publicity duties Aesch, January 23, 2014, 07.00 hrs - After the successful completion of the tender offer of Pharma Strategy Partners for Acino Holding AG (Acino), SIX Exchange Regulation of SIX Swiss Exchange (SIX) has, by decision dated December 23, 2013, exempted Acino from certain disclosure obligations under the Listing Rules of SIX for a limited period of time. A remaining shareholder of Acino has brought an appeal against this decision before the Appeal Body of SIX. With decision of January 22, 2014, the President of the Appeal Body of SIX has granted the appeal suspensive effect. On that basis, Acino will re-assume the publicity duties in accordance with articles 49 et seq. of the Listing Rules until further decision of the Appeal Body of SIX. About Acino

Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in up and coming economies, currently 80 countries in the Middle East, Africa, Latin America and Asia. The Acino Group, headquartered in Aesch BL, has 788 employees and generated revenues of EUR 143 million in the first half-year 2013.
On December 12, 2013, Pharma Strategy Partners GmbH, a wholly-owned subsidiary of Avista Capital Partners and Nordic Capital, successfully completed its public tender offer for Acino Holding AG. Pharma Strategy Partners GmbH intends to effect a full takeover of Acino, and will delist the Acino shares from the stock exchange.

Contact

Robert Schmid
Media & Investor Relations
Phone [phone] [e-mail]

Acino Holding AG

Dornacherstrasse 114

CH-4147 Aesch

Phone [phone]

Fax [phone] www.acino-pharma.com